Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hair Loss in Psychopharmacology

Hair Loss in Psychopharmacology Medication-induced alopecia is an occasional side effect of many psychopharmaceuticals. Most of the mood stabilizer and antidepressant drugs can lead to this condition. Some antipsychotic and antianxiety agents induce alopecia. Hair loss is also related to hypothyroidism, which can be induced by lithium and other agents. Alopecia might not be reported by some people, but physicians should be aware of this potential problem which may contribute to noncompliance. Lithium causes hair loss in 12–19% of long-term users. Valproic acid and/or divalproex precipitates alopecia in up to 12% of patients in a dose-dependent relationship. Incidences up to 28% are observed with high valproate concentration exposures. These pharmaceuticals also can change hair color and structure. The occurrence of carbamazepine-induced alopecia is at or below 6%. Hair loss is less common with other mood stabilizers. Tricyclic antidepressants, maprotilene, trazodone, and virtually all the new generation of antidepressants may on rare occasions lead to alopecia. The same applies to haloperidol, olanzepine, risperidone, clonazepam, and buspirone, but not to other neuroleptics, benzodiazepines, or barbiturates, selected antihistamines, and antiparkinsonians. Discontinuation of the medication or dose reduction almost always leads to complete hair regrowth. The therapeutic value of mineral supplements remains unclear. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Hair Loss in Psychopharmacology

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/hair-loss-in-psychopharmacology-8QO5IwQIE8
Publisher
Springer Journals
Copyright
Copyright © 2000 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1009074926921
Publisher site
See Article on Publisher Site

Abstract

Medication-induced alopecia is an occasional side effect of many psychopharmaceuticals. Most of the mood stabilizer and antidepressant drugs can lead to this condition. Some antipsychotic and antianxiety agents induce alopecia. Hair loss is also related to hypothyroidism, which can be induced by lithium and other agents. Alopecia might not be reported by some people, but physicians should be aware of this potential problem which may contribute to noncompliance. Lithium causes hair loss in 12–19% of long-term users. Valproic acid and/or divalproex precipitates alopecia in up to 12% of patients in a dose-dependent relationship. Incidences up to 28% are observed with high valproate concentration exposures. These pharmaceuticals also can change hair color and structure. The occurrence of carbamazepine-induced alopecia is at or below 6%. Hair loss is less common with other mood stabilizers. Tricyclic antidepressants, maprotilene, trazodone, and virtually all the new generation of antidepressants may on rare occasions lead to alopecia. The same applies to haloperidol, olanzepine, risperidone, clonazepam, and buspirone, but not to other neuroleptics, benzodiazepines, or barbiturates, selected antihistamines, and antiparkinsonians. Discontinuation of the medication or dose reduction almost always leads to complete hair regrowth. The therapeutic value of mineral supplements remains unclear.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Sep 30, 2004

References

  • Diseases of the Hair and Scalp
  • Diagnosis and management of the hair loss patient
    Stroud, JD
  • Advances in Modern Toxicology
    Reeves, JT; Maibach, HI
  • Alopecia: Diagnosis and management
    Nielsen, TA; Reichel, M
  • Antibodies to hair follicles in alopecia areata
    Tobin, DJ; Orentreich, N; Fenton, DA; Bystryn, JC
  • Clinical toxicity of chemotherapeutic agents: Dermatologic toxicity
    Dunagin, WG
  • Review: Drug-associated alopecia
    Pillans, PL; Woods, DJ
  • Drug-related alopecia
    Brodin, MB
  • Alopecia associated with gabapentin: First case [letter]
    Picard, C; Jonville-Bera, AP; Billard, C; Autret, E
  • Hair loss–An adverse reaction to treatment with vigabatrin
    Lampl, Y; Gillad, R; Savira-Pinchas, I; Barak, T
  • Adverse cutaneous reactions to psychotropic drugs
    Srebrnik, A; Hes, JP; Brenner, S
  • A review and controlled study of cutaneous conditions associated with lithium carbonate
    Sarantidis, D; Waters, B
  • Hair loss following lithium therapy
    Orwin, A
  • The impact of lithium in South West Scotland: Demographic and clinical findings
    McCreadie, RG; Morrison, DP
  • Lithium and hair loss.
    Jefferson, JW; Greist, JH; Diamond, RL
  • Hair loss in the course of lithium treatment: A report of 2 cases
    Yassa, R; Ananth, J
  • Hair loss and lithium
    Mortimer, PS; Dawber, RP
  • Clinically significant side effects of lithium treatment: A survey in long-term treatment
    Vestergaard, P; Amdisen, A; Schou, M
  • Alopecia areata during lithium therapy
    Silvestri, A; Santonastaso, P; Paggiarin, D
  • Cutaneous Side Effects of Drugs
    Bork, K
  • Thyroid disorders in lithium-treated patients
    Kirov, G
  • The prevalence of skin manifestations in thyrotoxicosis–A retrospective study
    Ramanathan, M; Abidin, MN; Muthukumarappan, M
  • Hair growth and alopecia in hypothyroidism
    Freinkel, RK; Freinkel, N
  • Alopecia of myxedema: Clinical response to levothyroxine sodium
    Signore, RJ; von Weiss, J.
  • Hair loss during lithium treatment
    Dawber, RP; Mortimer, PS
  • A cutaneous side effect of lithium
    Kusumi, Y
  • Hair loss in a patient receiving lithium
    Muniz, CE; Salem, RB; Director, KL
  • Lithium-induced reaction
    Eustace, DP
  • Report of a patient with lithium-related alopecia and psoriasis
    Ghadirian, AM; Lalinec-Michaud, M
  • Lithium and hair loss in childhood
    Wagner, KD; Teicher, MH
  • Valproic acid.Areappraisal of its pharmacological properties and clinical efficacy in epilepsy
    Davis, R; Peters, DH; McTavish, D
  • Alopecia and mood stabilizer therapy
    McKinney, PA; Finkenbine, RD; deVane, LC
  • Valproic acid in childhood epilepsy: Anticonvulsive efficacy in relation to plasma levels
    Klotz, U; Schweizer, C
  • Tolerance to and unwanted effects of valproate sodium
    Despland, PA
  • Clinical and pharmacokinetic observations on sodium valproate–A 5–year follow-up study in 100 children with epilepsy
    Henriksen, O; Johannessen, SI
  • Safety and efficacy of divalproex sodium monotherapy in partial epilepsy:A doubleblind, concentration-response design clinical trial
    Beydoun, A; Sackellares, JC; Shu, V
  • Alopecia and mood stabilizers: Two case reports
    Uehlinger, C; Barrelet, L; Touabi, M; Baumann, P
  • Long-term treatment with sodium valproate: Monitoring of venous ammonia concentrations and adverse effects
    Zaccara, G; Campostrini, R; Paganini, M; Messori, A; Valenza, T; Arnetoli, G; Zappoli, R
  • Treatment of valproate-induced alopecia
    Fatemi, SH; Calabrese, JR
  • The clinical significance of metal binding in convulsion control with sodium valproate
    Healy, MA; Aslam, MA
  • Analyses of serum copper and zinc levels and copper/zinc ratios in skin diseases
    Tasaki, M; Hanada, K; Hashimoto, I
  • Selenium, zinc, and copper changes in valproic acid: Possible relation to drug side effects
    Hurd, RW; Van Rinsvelt, HA; Wilder, BJ; Karas, B; Maenhaut, W; De Reu, L
  • The effects of antiepileptic drugs on serum zinc and copper levels in children
    Sozuer, DT; Barutcu, UB; Karakoc, Y; Yalcin, E; Onen, S
  • Serum copper and zinc levels in epileptic children with valproate treatment
    Kaji, M; Ito, M; Okuno, T; Momoi, T; Sasaki, H; Yamanaka, C; Yorifuji, T; Mikawa, H
  • Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics
    Suzuki, T; Koizumi, J; Moroji, T; Shiraishi, H; Hori, T; Baba, A; Kawai, N; Tada, K
  • Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients
    Kuzuya, T; Hasegawa, T; Shimizu, K; Nabeshima, T
  • Sodium valproate: Monotherapy and polytherapy
    Covanis, A; Gupta, AK; Jeavons, PM
  • Valproic acid, curly hair and weight gain
    Bittencourt, PR
  • Valproate and curly hair [letter]
    Jeavons, PM; Clark, JE; Harding, GE
  • Valproate in the treatment of persistent chronic daily headache. An open label study
    Mathew, NT; Ali, S
  • Change in hair colour induced by valproic acid
    Herranz, JL; Arteaga, R; Armijo, JA
  • “Perming” effect associated with chronic valproate therapy
    Gupta, AK
  • A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy
    Verity, CM; Hosking, G; Easter, DJ
  • A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults
    Mattson, RH; Cramer, JA; Collins, JF
  • Carbamazepine-induced hair loss
    Shuper, A; Stahl, B; Weitz, R
  • Propranolol and alopecia
    Hilder, RJ
  • Propranolol induced alopecia
    Martin, CM; Southwick, EG; Maibach, HI
  • Propranolol treatment
    Scribner, MD
  • Alopecia and propranolol therapy
    England, JR; England, JD
  • Alopecia with carbamazepine in two patients with focal seizures
    Ikeda, A; Shibasaki, H; Shiozaki, A; Kimura, J
  • Drug-related alopecia in patients treated with tricyclic antidepressants
    Warnock, JK; Sieg, K; Willsie, D; Stevenson, EK
  • Imipramine-induced alopecia areata-like lesions
    Baral, J; Deakins, S
  • Iatrogenic alopecia
    Friedman, M.
  • Imipramine in alopecia areata. A doubleblind, placebo-controlled study
    Perini, G; Zara, M; Cipriani, R; Carraro, C; Preti, A; Gava, F; Coghi, P; Peserico, A
  • Hair loss associated with fluoxetine use in two family members
    Mareth, TR
  • A comparison of fluvoxamine and fluoxetine in the treatment of major depression
    Rapaport, M; Coccaro, E; Sheline, Y; Perse, T; Holland, P; Fabre, L; Bradford, D
  • Hair loss associated with fluoxetine but not with citalopram
    Seifritz, E; Hatzinger, M; Muller, MJ; Hemmeter, U; Trachsler-Holsboer, E
  • Hair loss associated with fluoxetine treatment
    Ananth, J; Elmishaugh, A
  • Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation
    McDougle, CJ; Brodkin, ES; Naylor, ST; Carlson, DC; Cohen, DJ; Price, LH
  • Two cases of hair loss after sertraline use
    Bourgeois, J
  • Severe hair loss associated with fluoxetine use
    Jenike, MA
  • Hair loss during fluoxetine treatment
    Ogilvie, AD
  • Hair loss associated with fluoxetine
    Gupta, S; Major, LF
  • Fluoxetine-associated paresthesias and alopecia in awoman who tolerated sertraline
    Bhatara, VS; Gupta, S; Freeman, JW
  • Hair loss associated with fluvoxamine use
    Parameshwar, E
  • Hair loss associated with nefazodone
    Gupta, S; Gilroy, WR
  • Open treatment of obsessive-compulsive disorder with venlafaxine: A series of ten cases
    Rauch, SL; O'sullivan, RL; Jenike, MA
  • Alopecia areata associated with haloperidol
    Kubota, T; Ishikura, T; Jibiki, I
  • Diffuse alopecia in women
    Alexander, S
  • Hair loss in women
    Eckert, J; Church, RE; Ebling, FJ; Munro, DS